PRESS RELEASE
16 December 2022 10:40:00 CET

US clinical guidelines recommending Senzime's type of technology for neuromuscular monitoring are published

Uppsala, December 16, 2022. Senzime AB (publ) announced today that the American Society of Anesthesiologists (ASA) has now published the clinical guidelines for monitoring and reversal of neuromuscular blockade. This is the first time that ASA recommends neuromuscular monitoring.

ASA's new guidelines recommend against clinical assessment alone to avoid residual neuromuscular blockade when neuromuscular blocking drugs are administered, and the ASA strongly recommends quantitative monitoring over qualitative assessment to avoid residual neuromuscular blockade. For more information: **2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade**

"The guidelines confirm our technology and path forward for our TetraGraph system. This will further strengthen us on our journey to reduce critical complications of paralytic drugs and improving patient health", said Pia Renaudin, CEO of Senzime.

ASA is one of the foremost clinical and scientific societies in the world of anesthesia with over 55,000 members. To support healthcare providers with evidence-based recommendations, ASA develops various scientific and clinical guidelines that are published in the scientific journal, *Anesthesiology*. The new guidelines confirm that there is compelling evidence that these complications are underestimated, and that many patients are awakened while still exhibiting effects of neuromuscular blocking agents, such as residual neuromuscular weakness, leading to postoperative pulmonary complications, unpleasant recall, longer hospital stay and delayed return to daily activities.

In the US, Senzime markets innovative patient monitoring solutions, including TetraGraph, through its own sales organization. In June 2022, Senzime also signed a strategic license and connectivity agreement with Masimo, a US-headquartered and global leader in patient monitoring solutions.

About TetraGraph®
TetraGraph is a quantitative neuromuscular monitoring system based on the gold standard electromyography (EMG) technology, which provides accurate and versatile monitoring of neuromuscular blockade. The product is designed to monitor physiological data during surgery in patients receiving general anesthesia and muscle relaxation using muscle paralyzing drugs. TetraGraph stimulates the patient's peripheral nerve using the TetraSens disposable sensors and measures, analyzes, and displays hand muscle function in real time. Thanks to its small size and versatile features, the TetraGraph can be used in any type of surgery, anywhere in the hospital environment, and can be connected to external monitors and electronic hospital records.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB
Phone: +46 (0) 70-813 34 17, email: **pia.renaudin@senzime.com**

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at **senzime.com**.

Attachments

US clinical guidelines recommending Senzime's type of technology for neuromuscular monitoring are published